Treatment of Unfit Patients With Advanced Non-Small-Cell Lung Cancer: Definition Criteria According an Expert Panel

被引:24
作者
De Marinis, Filippo [1 ]
Bria, Emilio [2 ]
Baas, Paul [3 ]
Tiseo, Marcello [4 ]
Camerini, Andrea [5 ,6 ]
Favaretto, Adolfo Gino [7 ]
Gridelli, Cesare [8 ]
机构
[1] European Inst Oncol, Thorac Oncol Div, Milan, Italy
[2] Univ Verona, Azienda Osped Univ Integrata, Med Oncol, I-37100 Verona, Italy
[3] Netherlands Canc Inst, Thorac Oncol, Amsterdam, Netherlands
[4] Univ Hosp Parma, Med Oncol, Parma, Italy
[5] Versilia Hosp, Med Oncol, Lido Di Camaiore, Italy
[6] Ist Toscano Tumori, Lido Di Camaiore, Italy
[7] Ist Oncol Veneto IRCCS, Padua, Italy
[8] SG Moscati Hosp, Avellino, Italy
关键词
Chemotherapy; Lung cancer; Review; Treatment; Unfit; RANDOMIZED PHASE-III; COOPERATIVE-ONCOLOGY-GROUP; ELDERLY-PATIENTS; PERFORMANCE STATUS; SINGLE-AGENT; DOSE ADJUSTMENT; CHEMOTHERAPY; CISPLATIN; CARBOPLATIN; TRIAL;
D O I
10.1016/j.cllc.2015.04.008
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The assessment of special categories of non-small-cell lung cancer (NSCLC) patients requires a comprehensive analysis of all factors potentially influencing the daily quality of life and the relative contribution of tumor-related symptoms on the overall patient health status. While for elderly patients prospective evidence and recommendations allow clinicians to better address their patients to a shared treatment, a paucity of reliable data refers to treatment opportunities for these patients, termed frail or unfit, who are not considered eligible for chemotherapy usually administered to adult patients. This consensus was inspired by the absence of clear criteria to define the category of unfit patients in the context of advanced NSCLC in order to share all the available tools for their classification and evaluation and to support decisions for clinical practice on a daily basis. After review of the literature and panelist consensus, a series of items was identified as relevant: age, performance status, renal function, heart failure, previous cerebrovascular events, uncontrolled hypertension, neuropathy, hearing loss, symptomatic brain metastases, severe psychiatric disorders, and absence of caregiver support. On the basis of these factors, a treatment algorithm for clinical practice to categorize unfit NSCLC patient into 3 major clinical scenarios was defined: (1) unfit for cisplatinbased chemotherapy, (2) unfit for carboplatin-based chemotherapy, and (3) unfit for single-agent chemotherapy.
引用
收藏
页码:399 / 405
页数:7
相关论文
共 41 条
[31]   Management of elderly patients with NSCLC; updated expert's opinion paper: EORTC Elderly Task Force, Lung Cancer Group and International Society for Geriatric Oncology [J].
Pallis, A. G. ;
Gridelli, C. ;
Wedding, U. ;
Faivre-Finn, C. ;
Veronesi, G. ;
Jaklitsch, M. ;
Luciani, A. ;
O'Brien, M. .
ANNALS OF ONCOLOGY, 2014, 25 (07) :1270-1283
[32]   Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology [J].
Patel, Jyoti D. ;
Krilov, Lada ;
Adams, Sylvia ;
Aghajanian, Carol ;
Basch, Ethan ;
Brose, Marcia S. ;
Carroll, William L. ;
de Lima, Marcos ;
Gilbert, Mark R. ;
Kris, Mark G. ;
Marshall, John L. ;
Masters, Gregory A. ;
O'Day, Steven J. ;
Polite, Blase ;
Schwartz, Gary K. ;
Sharma, Sunil ;
Thompson, Ian ;
Vogelzang, Nicholas J. ;
Roth, Bruce J. .
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (02) :129-+
[33]   Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial [J].
Quoix, Elisabeth ;
Zalcman, Gerard ;
Oster, Jean-Philippe ;
Westeel, Virginie ;
Pichon, Eric ;
Lavole, Armelle ;
Dauba, Jerome ;
Debieuvre, Didier ;
Souquet, Pierre-Jean ;
Bigay-Game, Laurence ;
Dansin, Eric ;
Poudenx, Michel ;
Molinier, Olivier ;
Vaylet, Fabien ;
Moro-Sibilot, Denis ;
Herman, Dominique ;
Bennouna, Jaafar ;
Tredaniel, Jean ;
Ducolone, Alain ;
Lebitasy, Marie-Paule ;
Baudrin, Laurence ;
Laporte, Silvy ;
Milleron, Bernard .
LANCET, 2011, 378 (9796) :1079-1088
[34]   Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20 561 cases [J].
Radzikowska, E ;
Glaz, P ;
Roszkowski, K .
ANNALS OF ONCOLOGY, 2002, 13 (07) :1087-1093
[35]   Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].
Reck, M. ;
Popat, S. ;
Reinmuth, N. ;
De Ruysscher, D. ;
Kerr, K. M. ;
Peters, S. .
ANNALS OF ONCOLOGY, 2014, 25 :27-39
[36]   Treatment of Stage IV Non-small Cell Lung Cancer Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines [J].
Socinski, Mark A. ;
Evans, Tracey ;
Gettinger, Scott ;
Hensing, Thomas A. ;
Sequist, Lecia VanDam ;
Ireland, Belinda ;
Stinchcombe, Thomas E. .
CHEST, 2013, 143 (05) :E341-E368
[37]   Do all patients with advanced non-small-cell lung cancer benefit from cisplatin-based combination therapy? [J].
Soria, JC ;
Brisgand, D ;
Le Chevalier, T .
ANNALS OF ONCOLOGY, 2001, 12 (12) :1667-1670
[38]  
Sweeney CJ, 2001, CANCER, V92, P2639, DOI 10.1002/1097-0142(20011115)92:10<2639::AID-CNCR1617>3.0.CO
[39]  
2-8
[40]   How old is "too old" for translational research? [J].
Vergnenegre, Alain ;
Corre, Romain ;
Lena, Herve ;
Le Caer, Herve .
TRANSLATIONAL LUNG CANCER RESEARCH, 2014, 3 (02) :116-119